Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 23.856
SA - Sud America 4.066
EU - Europa 3.936
NA - Nord America 3.713
AF - Africa 331
OC - Oceania 63
Continente sconosciuto - Info sul continente non disponibili 6
Totale 35.971
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 11.817
SG - Singapore 4.052
CN - Cina 3.778
BR - Brasile 3.046
US - Stati Uniti d'America 2.879
HK - Hong Kong 1.718
IT - Italia 775
RU - Federazione Russa 756
KR - Corea 651
MX - Messico 578
TR - Turchia 421
DE - Germania 417
ES - Italia 403
AR - Argentina 365
ID - Indonesia 277
GB - Regno Unito 252
IN - India 242
JP - Giappone 238
FR - Francia 189
CO - Colombia 180
CA - Canada 170
EC - Ecuador 147
AT - Austria 140
BD - Bangladesh 129
NL - Olanda 115
CL - Cile 106
PL - Polonia 104
FI - Finlandia 100
ZA - Sudafrica 92
EG - Egitto 80
SA - Arabia Saudita 80
SE - Svezia 79
PK - Pakistan 72
GR - Grecia 68
PT - Portogallo 66
VE - Venezuela 64
UA - Ucraina 62
CH - Svizzera 58
IQ - Iraq 58
PY - Paraguay 58
PE - Perù 57
AU - Australia 52
CZ - Repubblica Ceca 49
IL - Israele 45
MA - Marocco 44
TW - Taiwan 41
HU - Ungheria 39
RO - Romania 35
DZ - Algeria 34
NO - Norvegia 32
HR - Croazia 29
BE - Belgio 28
MD - Moldavia 28
PH - Filippine 26
TN - Tunisia 26
UZ - Uzbekistan 25
AE - Emirati Arabi Uniti 24
UY - Uruguay 24
KE - Kenya 20
SK - Slovacchia (Repubblica Slovacca) 20
BO - Bolivia 19
CR - Costa Rica 19
DO - Repubblica Dominicana 19
KZ - Kazakistan 19
TH - Thailandia 19
GT - Guatemala 18
NP - Nepal 17
IE - Irlanda 16
DK - Danimarca 15
AZ - Azerbaigian 13
LB - Libano 12
MY - Malesia 11
NZ - Nuova Zelanda 11
OM - Oman 11
AL - Albania 10
SI - Slovenia 9
SN - Senegal 9
LK - Sri Lanka 8
LT - Lituania 8
RS - Serbia 8
BY - Bielorussia 7
GE - Georgia 7
HN - Honduras 7
SY - Repubblica araba siriana 7
IR - Iran 6
XK - ???statistics.table.value.countryCode.XK??? 6
BG - Bulgaria 5
BH - Bahrain 5
BW - Botswana 5
EE - Estonia 5
ET - Etiopia 5
JO - Giordania 5
LV - Lettonia 5
CI - Costa d'Avorio 4
PA - Panama 4
TT - Trinidad e Tobago 4
BN - Brunei Darussalam 3
JM - Giamaica 3
NG - Nigeria 3
NI - Nicaragua 3
Totale 35.930
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 3.808
Hanoi 3.008
Singapore 1.996
Hong Kong 1.677
Hefei 1.644
Seoul 614
Haiphong 316
Ashburn 310
Da Nang 310
São Paulo 300
Ha Long 290
Los Angeles 258
Quận Bình Thạnh 245
Buffalo 234
Biên Hòa 231
Dallas 225
Hải Dương 199
Ninh Bình 193
Thái Nguyên 185
Vũng Tàu 174
Milan 167
Can Tho 162
Moscow 151
Beijing 139
Bắc Ninh 139
Istanbul 137
Rio de Janeiro 124
Bắc Giang 118
The Dalles 115
Quận Một 113
Jakarta 112
Quận Phú Nhuận 106
Chicago 103
Phủ Lý 102
Madrid 100
Rome 97
Quận Sáu 88
Mexico City 85
Ankara 84
Shanghai 82
Vinh 77
Frankfurt am Main 74
Thái Bình 74
Lấp Vò 72
Guangzhou 71
New York 71
Quận Tân Phú 69
Uyen Hung 68
Bogotá 67
Lang Son 67
Tokyo 67
Curitiba 65
Điện Bàn 64
Vienna 63
Buenos Aires 62
Brasília 60
Vĩnh Tường 59
Quito 58
Quận Năm 58
Quảng Ninh 55
Thu Dau Mot 55
Barcelona 54
Belo Horizonte 54
Guadalajara 54
Nuremberg 53
Paris 50
Quận Bảy 50
Santiago 49
Thành Phố Bà Rịa 49
Bình Dương 46
Cologne 46
Hangzhou 46
Bến Tre 45
Goiânia 45
Lappeenranta 45
Huế 44
Hòa Bình 44
Karachi 44
Lima 44
Thanh Hóa 43
London 42
Manchester 42
Porto Alegre 42
Riyadh 42
Tam Bình 42
Bạc Liêu 40
Fortaleza 39
Nam Định 39
Quảng Ngãi 39
Salvador 39
Xi'an 39
Guayaquil 37
Medellín 37
Quận Mười 37
Ribeirão Preto 37
Athens 35
Bình An 35
Boston 34
Tây Ninh 34
Bologna 33
Totale 21.586
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 2.968
Classification criteria for autoinflammatory recurrent fevers 1.477
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.062
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 686
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 500
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 463
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 395
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 380
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 375
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 375
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 359
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 356
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 353
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 348
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 347
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 339
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 338
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 332
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 330
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 312
Localized scleroderma in childhood is not just a skin disease 310
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 300
Criteria to define response to therapy in paediatric rheumatic diseases 294
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 280
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 267
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 239
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 230
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 216
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 213
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 210
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 210
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 207
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 199
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 192
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 191
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 186
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 185
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 183
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 179
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 178
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 177
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 174
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 172
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 169
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 167
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 158
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 158
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 154
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 152
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 145
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 143
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 140
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 138
Adalimumab in Juvenile Rheumatoid Arthritis Reply 136
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 133
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 132
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 131
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 129
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 126
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 125
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 123
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 122
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 121
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 116
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 114
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 114
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 114
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 112
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 111
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 105
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 104
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 103
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate 103
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 101
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 101
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 100
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 99
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 99
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 96
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 94
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 93
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 86
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 86
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 86
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 85
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 85
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 84
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 83
Emerging therapies for juvenile arthritis: agents in early clinical trials 80
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 80
The Finnish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 80
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 79
Correction: A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry [Pediatr Rheumatol., 15, (2017) (84)] DOI: 10.1186/s12969-017-0213-x 79
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 78
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 75
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review 75
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 74
Correction to: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis (Arthritis Research & Therapy, (2024), 26, 1, (125), 10.1186/s13075-024-03347-0) 74
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 73
Totale 23.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.965
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.965
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202627.577 10.069 7.688 3.113 4.583 1.858 266 0 0 0 0 0 0
Totale 37.620